small molecule

CALQUENCE

ACALABRUTINIB

Loss of exclusivityJuly 2036latest FDA-listed patent expiry

CompanyASTRAZENECA UK LTD

Drug detail

Brand name	CALQUENCE
Active ingredient	ACALABRUTINIB
Strength	100MG
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	October 2017
Marketing status	RX

Listed patents

Patent	Expires	Type
10167291	July 2036	product
9796721	July 2036	substance, product
11166951	August 2035	use U-4427
10272083	January 2035	use U-4109
11771696	January 2035	use U-3710
10239883	July 2032	use U-2666
9758524	July 2032	use U-2145
9290504	July 2032	substance, product
7459554	November 2026	substance

Regulatory exclusivity

Code	Expires
D-200	February 2029
I-960	January 2028
ODE-274	November 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from ASTRAZENECA UK LTD